ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet9553ometendo-9553Research ArticleОбзор литературыReviewЖелчнокаменная болезнь как клинический маркер метаболического синдромаGallstone disease as a clinical marker of metabolic syndromehttps://orcid.org/0000-0003-1592-5703СвистуновАндрей АлексеевичSvistunovAndrey A.

д.м.н., проф., член-корреспондент РАН

MD, PhD, Professor

svistunov@sechenov.ruhttps://orcid.org/0000-0003-0485-6802ОсадчукМихаил АлексеевичOsadchukMiсhail A.

д.м.н., профессор

MD, PhD, Professor

osadchuk.mikhail@yandex.ruhttps://orcid.org/0000-0002-3467-886XКирееваНаталья ВикторовнаKireevaNatalia V.

к.м.н., доцент

MD, PhD, Associate Professor

kireeva_nat@inbox.ruhttps://orcid.org/0000-0002-8488-9235ОсадчукАлексей МихайловичOsadchukAlexey M.

д.м.н., профессор

MD, PhD, Professor

maxlife2004@mail.ru<p>ФГАОУ ВО &laquo;Первый Московский государственный медицинский университет им. И.М. Сеченова&raquo; Министерства здравоохранения Российской Федерации (Сеченовский Университет)</p>Россия<p>I.M. Sechenov First Moscow State Medical University (Sechenov University)</p>Russian Federation<p>ФГАОУ ВО &laquo;Первый Московский государственный медицинский университет им. И.М. Сеченова&raquo; Министерства&nbsp;здравоохранения Российской Федерации (Сеченовский Университет)</p>Россия<p>I.M. Sechenov First Moscow State Medical University (Sechenov University)</p>Russian Federation<p>ФГБОУ ВО &laquo;Самарский государственный медицинский университет&raquo; Министерства здравоохранения Российской Федерации</p>Россия<p>Samara State Medical University</p>Russian Federation20182311201815338Copyright &#x00A9; Свистунов А.А., Осадчук М.А., Киреева Н.В., Осадчук А.М., 20182018Свистунов А.А., Осадчук М.А., Киреева Н.В., Осадчук А.М.Svistunov A.A., Osadchuk M.A., Kireeva N.V., Osadchuk A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/9553

Распространенность желчнокаменной болезни, ее тесная патогенетическая связь с метаболическим синдромом, высокая частота хирургического вмешательства, значительные экономические потери выдвигают данную коморбидную патологию в ряд ведущих проблем современной клинической медицины. Факторы, ассоциированные с метаболическим синдромом, не только повышают риск развития желчнокаменной болезни, но и формируют основу немедикаментозной и медикаментозной терапии. Метаболический синдром часто определяет возникновение трех распространенных и потенциально опасных для жизни осложнений холелитиаза: острый холецистит, острый холангит и билиарный панкреатит. Поэтому решение данной проблемы связано с необходимостью раннего выявления дополнительных факторов риска холелитиаза, оптимизации ранней диагностической и прогностической модели существующей полиорганной патологии с целью уменьшения прогрессирования заболевания и его осложнений. Полученные в последние годы данные по геному человека с метаболическим синдромом и желчнокаменной болезнью дают возможность прогнозировать развитие коморбидной патологии и в полной мере обеспечивать результативность первичной профилактики.

The prevalence of cholelithiasis, its close pathogenetic connection with metabolic syndrome, high frequency of surgical intervention, significant economic losses put forward this comorbid pathology in a number of leading problems of modern clinical medicine. The factors associated with the metabolic syndrome not only increase the risk of developing cholelithiasis, but also form the basis of non-drug and drug therapy. Metabolic syndrome often determines the occurrence of three common and potentially life-threatening complications of cholelithiasis: acute cholecystitis, acute cholangitis and biliary pancreatitis. Therefore, the solution of this problem is associated with the need for early detection of additional risk factors for cholelithiasis, optimization of the early diagnostic and prognostic model of existing multi-organ pathology with the aim of reducing the progression of the disease and its complications. The data obtained in recent years on the human genome with metabolic syndrome and cholelithiasis make it possible to predict the development of comorbid pathology and to fully ensure the effectiveness of primary prevention.

желчнокаменная болезньхолелитиазметаболический синдромгенетикаожирениеишемическая болезнь сердцаартериальная гипертензияпрофилактикаgallstonescholelithiasismetabolic syndromegeneticsabdominal obesityischemic heart diseasehypertensionpreventionReferencesHoffman EL, VonWald T, Hansen K. The metabolic syndrome. S. D. Med. 2015;Spec No:24-28.Hoffman EL, VonWald T, Hansen K. The metabolic syndrome. S. D. Med. 2015;Spec No:24-28.Halmos T, Suba I. A nem alkoholos zsírmáj mint a metabolikus szindróma komponense és kauzális kapcsolatai egyéb kórképekkel. Orv. Hetil. 2017;158(52):2051-2061. doi: 10.1556/650.2017.30936.Halmos T, Suba I. A nem alkoholos zsírmáj mint a metabolikus szindróma komponense és kauzális kapcsolatai egyéb kórképekkel. Orv. Hetil. 2017;158(52):2051-2061. doi: 10.1556/650.2017.30936.Chen L-Y. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012;18(31):4215. doi: 10.3748/wjg.v18.i31.4215.Chen L-Y. Metabolic syndrome and gallstone disease. World J. Gastroenterol. 2012;18(31):4215. doi: 10.3748/wjg.v18.i31.4215.Di Ciaula A, Wang DQH, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Current Opinion in Gastroenterology. 2018;34(2):71-80. doi: 10.1097/mog.0000000000000423.Di Ciaula A, Wang DQH, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Current Opinion in Gastroenterology. 2018;34(2):71-80. doi: 10.1097/mog.0000000000000423.Lammert F, Neubrand M, Bittner R, et al. Kurzfassung der aktualisierten S3-Leitlinie der DGVS und DGVC zur Diagnostik und Behandlung von Gallensteinen. DMW - Deutsche Medizinische Wochenschrift. 2008;133(7):311-316. doi: 10.1055/s-2008-1046712Lammert F, Neubrand M, Bittner R, et al. Kurzfassung der aktualisierten S3-Leitlinie der DGVS und DGVC zur Diagnostik und Behandlung von Gallensteinen. DMW - Deutsche Medizinische Wochenschrift. 2008;133(7):311-316. doi: 10.1055/s-2008-1046712Ruhl CE, Everhart JE. Relationship of Non-alcoholic Fatty Liver Disease With Cholecystectomy in the US Population. The American Journal of Gastroenterology. 2013;108(6):952-958. doi: 10.1038/ajg.2013.70.Ruhl CE, Everhart JE. Relationship of Non-alcoholic Fatty Liver Disease With Cholecystectomy in the US Population. The American Journal of Gastroenterology. 2013;108(6):952-958. doi: 10.1038/ajg.2013.70.Schulz C, Jiang Z-Y, Sheng X, et al. Gallbladder Gallstone Disease Is Associated with Newly Diagnosed Coronary Artery Atherosclerotic Disease: A Cross-Sectional Study. PLoS One. 2013;8(9):e75400. doi: 10.1371/journal.pone.0075400.Schulz C, Jiang Z-Y, Sheng X, et al. Gallbladder Gallstone Disease Is Associated with Newly Diagnosed Coronary Artery Atherosclerotic Disease: A Cross-Sectional Study. PLoS One. 2013;8(9):e75400. doi: 10.1371/journal.pone.0075400.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». // Ожирение и метаболизм. – 2016 – Т.13. — №1. С. 36-44. [Dedov II, Mel'nichenko GA, Romantsova TyI. The strategy of obesity management: the results of All-Russian observational program “Primavera”. Obesity and metabolism. 2016;13(1):36-44. (In Russ).] doi: 10.14341/omet2016136-44.Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». // Ожирение и метаболизм. – 2016 – Т.13. — №1. С. 36-44. [Dedov II, Mel'nichenko GA, Romantsova TyI. The strategy of obesity management: the results of All-Russian observational program “Primavera”. Obesity and metabolism. 2016;13(1):36-44. (In Russ).] doi: 10.14341/omet2016136-44.Portincasa P, Di Ciaula A, de Bari O, et al. Management of gallstones and its related complications. Expert Review of Gastroenterology & Hepatology. 2015;10(1):93-112. doi: 10.1586/17474124.2016.1109445.Portincasa P, Di Ciaula A, de Bari O, et al. Management of gallstones and its related complications. Expert Review of Gastroenterology & Hepatology. 2015;10(1):93-112. doi: 10.1586/17474124.2016.1109445.Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation – a new data cohort study and a systematic review with meta-analysis. Scand. J. Gastroenterol. 2016;51(10):1239-1248. doi: 10.1080/00365521.2016.1182583.Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation – a new data cohort study and a systematic review with meta-analysis. Scand. J. Gastroenterol. 2016;51(10):1239-1248. doi: 10.1080/00365521.2016.1182583.Lammert F, Miquel J-F. Gallstone disease: From genes to evidence-based therapy. J. Hepatol. 2008;48:S124-S135. doi: 10.1016/j.jhep.2008.01.012.Lammert F, Miquel J-F. Gallstone disease: From genes to evidence-based therapy. J. Hepatol. 2008;48:S124-S135. doi: 10.1016/j.jhep.2008.01.012.Munnich A, Feingold J. Book Review: The Genetic Basis of Common Diseases (Oxford Monographs on Medical Genetics.). Second edition. Edited by King RA, Rotter JI, Motulsky AG.. 1076 pp., illustrated. New York, Oxford University. N. Engl. J. Med. 2003;349(4):410-410. doi: 10.1056/nejm200307243490423.Munnich A, Feingold J. Book Review: The Genetic Basis of Common Diseases (Oxford Monographs on Medical Genetics.). Second edition. Edited by King RA, Rotter JI, Motulsky AG.. 1076 pp., illustrated. New York, Oxford University. N. Engl. J. Med. 2003;349(4):410-410. doi: 10.1056/nejm200307243490423.Ferrer M, Ruiz A, Lanza F, et al. Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environ. Microbiol. 2013;15(1):211-226. doi: 10.1111/j.1462-2920.2012.02845.x.Ferrer M, Ruiz A, Lanza F, et al. Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environ. Microbiol. 2013;15(1):211-226. doi: 10.1111/j.1462-2920.2012.02845.x.He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell & Bioscience. 2017;7(1). doi: 10.1186/s13578-017-0183-1.He M, Shi B. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell & Bioscience. 2017;7(1). doi: 10.1186/s13578-017-0183-1.Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: A Swedish study of 43,141 twin pairs. Hepatology. 2005;41(5):1138-1143. doi: 10.1002/hep.20654.Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: A Swedish study of 43,141 twin pairs. Hepatology. 2005;41(5):1138-1143. doi: 10.1002/hep.20654.Lyons MA, Wittenburg H. Cholesterol Gallstone Susceptibility Loci: A Mouse Map, Candidate Gene Evaluation, and Guide to Human LITH Genes. Gastroenterology. 2006;131(6):1943-1970. doi: 10.1053/j.gastro.2006.10.024.Lyons MA, Wittenburg H. Cholesterol Gallstone Susceptibility Loci: A Mouse Map, Candidate Gene Evaluation, and Guide to Human LITH Genes. Gastroenterology. 2006;131(6):1943-1970. doi: 10.1053/j.gastro.2006.10.024.Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones. Ann. Surg. 2002;235(6):842-849. doi: 10.1097/00000658-200206000-00012.Nakeeb A, Comuzzie AG, Martin L, et al. Gallstones. Ann. Surg. 2002;235(6):842-849. doi: 10.1097/00000658-200206000-00012.Grünhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology. 2007;46(3):793-801. doi: 10.1002/hep.21847.Grünhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology. 2007;46(3):793-801. doi: 10.1002/hep.21847.Elferink RPJO, Paulusma CC, Groen AK. Hepatocanalicular Transport Defects: Pathophysiologic Mechanisms of Rare Diseases. Gastroenterology. 2006;130(3):908-925. doi: 10.1053/j.gastro.2005.08.052.Elferink RPJO, Paulusma CC, Groen AK. Hepatocanalicular Transport Defects: Pathophysiologic Mechanisms of Rare Diseases. Gastroenterology. 2006;130(3):908-925. doi: 10.1053/j.gastro.2005.08.052.Acalovschi M, Ciocan A, Mostean O, et al. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? Eur. J. Intern. Med. 2006;17(7):490-494. doi: 10.1016/j.ejim.2006.04.012.Acalovschi M, Ciocan A, Mostean O, et al. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? Eur. J. Intern. Med. 2006;17(7):490-494. doi: 10.1016/j.ejim.2006.04.012.Matyjas T, Kaczka K, Witas H, et al. Cholelithiasis - always infected? Pol. Przegl. Chir. 2017;89(3):23-26.Matyjas T, Kaczka K, Witas H, et al. Cholelithiasis - always infected? Pol. Przegl. Chir. 2017;89(3):23-26.Wittenburg H, Lyons MA, Li R, et al. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology. 2003;125(3):868-881. doi: 10.1016/s0016-5085(03)01053-9.Wittenburg H, Lyons MA, Li R, et al. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology. 2003;125(3):868-881. doi: 10.1016/s0016-5085(03)01053-9.Kajinami K, Brousseau ME, Nartsupha C, et al. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 2004;45(4):653-656. doi: 10.1194/jlr.M300278-JLR200.Kajinami K, Brousseau ME, Nartsupha C, et al. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 2004;45(4):653-656. doi: 10.1194/jlr.M300278-JLR200.Mandell MS, Xue P, Niu W-Q, et al. A Meta-Analysis of Apolipoprotein E Gene ε2/ε3/ε4 Polymorphism for Gallbladder Stone Disease. PLoS One. 2012;7(9):e45849. doi: 10.1371/journal.pone.0045849.Mandell MS, Xue P, Niu W-Q, et al. A Meta-Analysis of Apolipoprotein E Gene ε2/ε3/ε4 Polymorphism for Gallbladder Stone Disease. PLoS One. 2012;7(9):e45849. doi: 10.1371/journal.pone.0045849.Koeijvoets KCMC, van der Net JB, Dallinga-Thie GM, et al. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis. 2009;204(2):453-458. doi: 10.1016/j.atherosclerosis.2008.09.018.Koeijvoets KCMC, van der Net JB, Dallinga-Thie GM, et al. ABCG8 gene polymorphisms, plasma cholesterol concentrations, and risk of cardiovascular disease in familial hypercholesterolemia. Atherosclerosis. 2009;204(2):453-458. doi: 10.1016/j.atherosclerosis.2008.09.018.Kountouras J, Boziki M, Polyzos SA, et al. The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Curr. Mol. Med. 2017;17(6):389-404.doi: 10.2174/1566524018666171219094837.Kountouras J, Boziki M, Polyzos SA, et al. The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. Curr. Mol. Med. 2017;17(6):389-404.doi: 10.2174/1566524018666171219094837.Mokhtare M, Mirfakhraee H, Arshad M, et al. The effects of helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia. Diabetes Metab Syndr. 2017;11 Suppl 2:S1031-S1035. doi: 10.1016/j.dsx.2017.07.035..Mokhtare M, Mirfakhraee H, Arshad M, et al. The effects of helicobacter pylori eradication on modification of metabolic syndrome parameters in patients with functional dyspepsia. Diabetes Metab Syndr. 2017;11 Suppl 2:S1031-S1035. doi: 10.1016/j.dsx.2017.07.035..Tang DM, Kumar S. The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Current gastroenterology reports. 2017;19(2). doi: 10.1007/s11894-017-0545-1.Tang DM, Kumar S. The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Current gastroenterology reports. 2017;19(2). doi: 10.1007/s11894-017-0545-1.Cen L, Pan J, Zhou B, et al. Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis. Helicobacter. 2018;23(1):e12457. doi: 10.1111/hel.12457.Cen L, Pan J, Zhou B, et al. Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta-analysis. Helicobacter. 2018;23(1):e12457. doi: 10.1111/hel.12457.Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. Endocrine. 2018;61(3):357-371. doi: 10.1007/s12020-018-1605-5.Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. Endocrine. 2018;61(3):357-371. doi: 10.1007/s12020-018-1605-5.Capoor MR, Nair D, Rajni, et al. Microflora of bile aspirates in patients with acute cholecystitis With or without cholelithiasis: a tropical experience. Braz. J. Infect. Dis. 2008;12(3). doi: 10.1590/s1413-86702008000300012.Capoor MR, Nair D, Rajni, et al. Microflora of bile aspirates in patients with acute cholecystitis With or without cholelithiasis: a tropical experience. Braz. J. Infect. Dis. 2008;12(3). doi: 10.1590/s1413-86702008000300012.White JS, Hoper M, Parks RW, et al. Patterns of Bacterial Translocation in Experimental Biliary Obstruction. J. Surg. Res. 2006;132(1):80-84. doi: 10.1016/j.jss.2005.07.026.White JS, Hoper M, Parks RW, et al. Patterns of Bacterial Translocation in Experimental Biliary Obstruction. J. Surg. Res. 2006;132(1):80-84. doi: 10.1016/j.jss.2005.07.026.Di Ciaula A, Garruti G, Baccetto RL, et al. Bile Acid Physiology. Ann. Hepatol. 2017;16(0):4-14. doi: 10.5604/01.3001.0010.5493.Di Ciaula A, Garruti G, Baccetto RL, et al. Bile Acid Physiology. Ann. Hepatol. 2017;16(0):4-14. doi: 10.5604/01.3001.0010.5493.Tsai CJ. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006;55(5):708-714. doi: 10.1136/gut.2005.076133.Tsai CJ. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006;55(5):708-714. doi: 10.1136/gut.2005.076133.Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80(1):38-44. doi: 10.1093/ajcn/80.1.38..Tsai C-J, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80(1):38-44. doi: 10.1093/ajcn/80.1.38..Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 2006;45(2):299-305. doi: 10.1016/j.jhep.2006.01.026.Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J. Hepatol. 2006;45(2):299-305. doi: 10.1016/j.jhep.2006.01.026.Mella JG, Schirin-Sokhan R, Rigotti A, et al. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations. J. Lipid Res. 2007;48(6):1378-1385. doi: 10.1194/jlr.M700059-JLR200.Mella JG, Schirin-Sokhan R, Rigotti A, et al. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations. J. Lipid Res. 2007;48(6):1378-1385. doi: 10.1194/jlr.M700059-JLR200.Yu K-j, Zhang J-r, Li Y, et al. Gallstone disease is associated with arterial stiffness progression. Hypertens. Res. 2016;40(1):31-34. doi: 10.1038/hr.2016.109.Yu K-j, Zhang J-r, Li Y, et al. Gallstone disease is associated with arterial stiffness progression. Hypertens. Res. 2016;40(1):31-34. doi: 10.1038/hr.2016.109.Sattar N, Gaw A, Scherbakova O, et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-419. doi: 10.1161/01.cir.0000080897.52664.94.Sattar N, Gaw A, Scherbakova O, et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-419. doi: 10.1161/01.cir.0000080897.52664.94.Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, et al. Strong Association between Gallstones and Cardiovascular Disease. Am J Gastroenterol. 2005;100(4):827-830. doi: 10.1111/j.1572-0241.2005.41214.x.Mendez-Sanchez N, Bahena-Aponte J, Chavez-Tapia NC, et al. Strong Association between Gallstones and Cardiovascular Disease. Am J Gastroenterol. 2005;100(4):827-830. doi: 10.1111/j.1572-0241.2005.41214.x.Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand. J. Gastroenterol. 2011;47(2):197-203. doi: 10.3109/00365521.2011.643481.Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand. J. Gastroenterol. 2011;47(2):197-203. doi: 10.3109/00365521.2011.643481.Arslan U, Turkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron. Artery Dis. 2007;18(6):433-436. doi: 10.1097/MCA.0b013e3282583c0d.Arslan U, Turkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron. Artery Dis. 2007;18(6):433-436. doi: 10.1097/MCA.0b013e3282583c0d.Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. Circulation. 2009;120(16):1640-1645. doi: 10.1161/circulationaha.109.192644.Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. Circulation. 2009;120(16):1640-1645. doi: 10.1161/circulationaha.109.192644.van der Wulp MYM, Verkade HJ, Groen AK. Regulation of cholesterol homeostasis. Mol. Cell. Endocrinol. 2013;368(1-2):1-16. doi: 10.1016/j.mce.2012.06.007.van der Wulp MYM, Verkade HJ, Groen AK. Regulation of cholesterol homeostasis. Mol. Cell. Endocrinol. 2013;368(1-2):1-16. doi: 10.1016/j.mce.2012.06.007.Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 2009;50(Supplement):S189-S194. doi: 10.1194/jlr.R800088-JLR200.Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 2009;50(Supplement):S189-S194. doi: 10.1194/jlr.R800088-JLR200.Jiang Z-Y, Parini P, Eggertsen G, et al. Increased expression ofLXRα,ABCG5,ABCG8, andSR-BIin the liver from normolipidemic, nonobese Chinese gallstone patients. J. Lipid Res. 2008;49(2):464-472. doi: 10.1194/jlr.M700295-JLR200.Jiang Z-Y, Parini P, Eggertsen G, et al. Increased expression ofLXRα,ABCG5,ABCG8, andSR-BIin the liver from normolipidemic, nonobese Chinese gallstone patients. J. Lipid Res. 2008;49(2):464-472. doi: 10.1194/jlr.M700295-JLR200.Schwartz C, Halloran L, Vlahcevic Z, et al. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science. 1978;200(4337):62-64. doi: 10.1126/science.204996.Schwartz C, Halloran L, Vlahcevic Z, et al. Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man. Science. 1978;200(4337):62-64. doi: 10.1126/science.204996.Robins SJ, Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J. Clin. Invest. 1997;99(3):380-384. doi: 10.1172/jci119170.Robins SJ, Fasulo JM. High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J. Clin. Invest. 1997;99(3):380-384. doi: 10.1172/jci119170.Kim JM, Lee HL, Moon W, et al. Association between insulin, insulin resistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-187.Kim JM, Lee HL, Moon W, et al. Association between insulin, insulin resistance, and gallstone disease in Korean general population. Korean J Gastroenterol. 2007;50(3):183-187.Shabanzadeh DM, Skaaby T, Sørensen LT, et al. Metabolic biomarkers and gallstone disease – a population-based study. Scand. J. Gastroenterol. 2017;52(11):1270-1277. doi: 10.1080/00365521.2017.1365166.Shabanzadeh DM, Skaaby T, Sørensen LT, et al. Metabolic biomarkers and gallstone disease – a population-based study. Scand. J. Gastroenterol. 2017;52(11):1270-1277. doi: 10.1080/00365521.2017.1365166.Wu Q, He X-D, Yu L, et al. The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China. Asian Pac. J. Cancer Prev. 2012;13(5):1963-1969. doi: 10.7314/apjcp.2012.13.5.1963.Wu Q, He X-D, Yu L, et al. The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China. Asian Pac. J. Cancer Prev. 2012;13(5):1963-1969. doi: 10.7314/apjcp.2012.13.5.1963.Su K, Sabeva NS, Liu J, et al. The ABCG5 ABCG8 Sterol Transporter Opposes the Development of Fatty Liver Disease and Loss of Glycemic Control Independently of Phytosterol Accumulation. J. Biol. Chem. 2012;287(34):28564-28575. doi: 10.1074/jbc.M112.360081.Su K, Sabeva NS, Liu J, et al. The ABCG5 ABCG8 Sterol Transporter Opposes the Development of Fatty Liver Disease and Loss of Glycemic Control Independently of Phytosterol Accumulation. J. Biol. Chem. 2012;287(34):28564-28575. doi: 10.1074/jbc.M112.360081.Min H-K, Kapoor A, Fuchs M, et al. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metab. 2012;15(5):665-674. doi: 10.1016/j.cmet.2012.04.004.Min H-K, Kapoor A, Fuchs M, et al. Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metab. 2012;15(5):665-674. doi: 10.1016/j.cmet.2012.04.004.Arrese M, Cortés V, Barrera F, Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy. Current Opinion in Gastroenterology. 2018;34(2):90-96. doi: 10.1097/mog.0000000000000416.Arrese M, Cortés V, Barrera F, Nervi F. Nonalcoholic fatty liver disease, cholesterol gallstones, and cholecystectomy. Current Opinion in Gastroenterology. 2018;34(2):90-96. doi: 10.1097/mog.0000000000000416.Cortés V, Quezada N, Uribe S, et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study. Lipids Health Dis. 2017;16(1). doi: 10.1186/s12944-017-0525-3.Cortés V, Quezada N, Uribe S, et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study. Lipids Health Dis. 2017;16(1). doi: 10.1186/s12944-017-0525-3.Byrne CD, Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015;62(1):S47-S64. doi: 10.1016/j.jhep.2014.12.012.Byrne CD, Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015;62(1):S47-S64. doi: 10.1016/j.jhep.2014.12.012.Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology. 2014;28(4):637-653. doi: 10.1016/j.bpg.2014.07.008.Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology. 2014;28(4):637-653. doi: 10.1016/j.bpg.2014.07.008.Ahmed F, Baloch Q, Memon ZA, Ali I. An observational study on the association of nonalcoholic fatty liver disease and metabolic syndrome with gall stone disease requiring cholecystectomy. Annals of Medicine and Surgery. 2017;17:7-13. doi: 10.1016/j.amsu.2017.03.015.Ahmed F, Baloch Q, Memon ZA, Ali I. An observational study on the association of nonalcoholic fatty liver disease and metabolic syndrome with gall stone disease requiring cholecystectomy. Annals of Medicine and Surgery. 2017;17:7-13. doi: 10.1016/j.amsu.2017.03.015.Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nature Reviews Disease Primers. 2016;2:16024. doi: 10.1038/nrdp.2016.24.Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nature Reviews Disease Primers. 2016;2:16024. doi: 10.1038/nrdp.2016.24.

The authors declare that there are no conflicts of interest present.